Very early initiation of statin therapy and mortality in patients with acute coronary syndrome

References

• Nusca A, Melfi R, Patti G, Di Sciascio G. Statin loading for acute coronary syndromes. Curr Opin Cardiol. 2010;25:373–8.
   Google Scholar
• Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: A systematic review of randomized trials. Am J Cardiovasc Drugs 2007;7:135–41.
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, Bridges CR, , Casey DE JrEttinger SM, . 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the American academy of family physicians, society for cardiovascular angiography and interventions, and the society of thoracic surgeons. J Am Coll Cardiol. 2011;57:e215–367
   PubMedGoogle Scholar
• Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, . Updated evidence on early statin therapy for acute coronary syndromes: Meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2011;Feb 3, [Epub Ahead of print].
   Google Scholar
• Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896–900.
   PubMed Web of Science ®Google Scholar
• Sutton A, Abrams K, Jones D. Methods for meta-analysis in medical research. Wiley series in probability and statistics, John Wiley & Sons Ltd, Chichesterl; 2000.
   Google Scholar
• Whitehead A. Estimating the treatment difference in an individual trial. In: Meta-analysis of controlled clinical trials. Chichester: John Wiley & Sons Ltd; 2002, pp. 23–50.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327:557–60
   PubMed Web of Science ®Google Scholar
• Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–75.
   PubMed Web of Science ®Google Scholar
• Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, . Beneficial effects of pravastatin(+/− colestyramine/niacin) initiated immediately after a coronary event (the randomized lipid-coronary artery disease (l-CAD) study). Am J Cardiol. 2000; 86:1293–8.
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Guido V, Tubaro M, Ammirati F, Montefoschi N, Varveri A, . Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-q-wave myocardial infarction. Am J Cardiol. 2002;90:872–4.
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, . Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase z of the a to z trial. JAMA 2004;292:1307–16.
   PubMed Web of Science ®Google Scholar
• Den Hartog FR, Van Kalmthout PM, Van Loenhout TT, Schaafsma HJ, Rila H, Verheugt FW. Pravastatin in acute ischaemic syndromes: Results of a randomised placebo-controlled trial. Int J Clin Pract. 2001;55:300–4.
   Google Scholar
• Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The Recife (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227–33.
   PubMed Web of Science ®Google Scholar
• Kayikcioglu M, Can L, Kultursay H, Payzin S, Turkoglu C. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiol. 2002;57: 295–302.
   Google Scholar
• Kesteloot H, Claeys G, Blanckaert N, Lesaffre E. Time course of serum lipids and apolipoproteins after acute myocardial infarction: Modification by pravastatin. Acta Cardiol. 1997;52:107–16.
   Google Scholar
• Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, . Effect of fluvastatin on ischaemia following acute myocardial infarction: A randomized trial. Eur Heart J. 2002;23:1931–7.
   PubMed Web of Science ®Google Scholar
• Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, . Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo-controlled study. Am Heart J. 2005;149:451–7.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, . Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The establish study. Circulation 2004;110:1061–8.
   PubMed Web of Science ®Google Scholar
• Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, . Fluvastatin in the first-line therapy of acute coronary syndrome: Results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). Trials 2010;11:61.
   Google Scholar
• Ren HZ, Ma LL, Wang LX. Effect of simvastatin on plasma interleukin-6 in patients with unstable angina. Clin Invest Med. 2009;32:E280–4.
   Google Scholar
• Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, . Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol. 2006;97:1165–71.
   PubMed Web of Science ®Google Scholar
• Sato H, Kinjo K, Ito H, Hirayama A, Nanto S, Fukunami M, . Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: The OACIS-lipid study. Circ J. 2008;72:17–22.
   Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711–8.
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, . Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287:3215–22.
   PubMed Web of Science ®Google Scholar
• Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The pravastatin in acute coronary treatment (PACT) trial. Am Heart J. 2004;148:e2.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350: 1495–504.
   PubMed Web of Science ®Google Scholar
• Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: A meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814–21.
   PubMed Web of Science ®Google Scholar
• Kim MC, Ahn Y, Cho KH, Lee MG, Ko JS, Park KH, . Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction. Int Heart J. 2011;52:1–6.
   Google Scholar
• Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, . An hmg-coa reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metallo proteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276–83.
   PubMed Web of Science ®Google Scholar
• Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, . Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999;33:1294–304.
   PubMed Web of Science ®Google Scholar
• Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors. Circulation 1998;97:1129–35.
   PubMed Web of Science ®Google Scholar
• Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol. 1999;10:435–41.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of c-reactive protein. The cholesterol and recurrent events (care) investigators. Circulation 1999;100:230–5.
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on c-reactive protein levels: The pravastatin inflammation/crp evaluation (prince): A randomized trial and cohort study. JAMA 2001;286:64–70.
   PubMed Web of Science ®Google Scholar
• Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001;103:926–33.
   PubMed Web of Science ®Google Scholar
• Eto M, Luscher TF. Modulation of coagulation and fibrinolytic pathways by statins. Endothelium 2003;10:35–41.
   PubMed Web of Science ®Google Scholar